Feb 23 (Reuters) -
* HEALTH CANADA APPROVES DUPIXENT® (DUPILUMAB INJECTION) AS THE FIRST BIOLOGIC FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHILDREN AGED 6 TO 11 YEARS
Feb 23 (Reuters) -
* HEALTH CANADA APPROVES DUPIXENT® (DUPILUMAB INJECTION) AS THE FIRST BIOLOGIC FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHILDREN AGED 6 TO 11 YEARS